Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Lasmiditan OD vs IR in Healthy Subjects
NCT04881747Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lasmiditan in migraine (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration of Lasmiditan, Area Under the Concentration Versus Time Curve From Time Zero to Infinity and 1 more. Started May 2021; status: completed.
02
Drugs
lasmiditan
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04881747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04881747.